{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:56:09Z","timestamp":1791060969669,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577153"],"award-info":[{"award-number":["22577153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20252069"],"award-info":[{"award-number":["BK20252069"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118506","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:45:35Z","timestamp":1790462735000},"page":"118506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Lysine-targeted covalent inhibitors: mechanistic advances, pharmacological perspectives and translational challenges"],"prefix":"10.1016","volume":"254","author":[{"given":"Mingjin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-2793","authenticated-orcid":false,"given":"Guoshun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118506_b0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118506_b0010","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/acs.jmedchem.4c02661","article-title":"A medicinal chemistry perspective on FDA-approved small molecule drugs with a covalent mechanism of action","volume":"68","author":"Dalton","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118506_b0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118506_b0025","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118506_b0030","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/acs.jctc.3c00232","article-title":"Integrated covalent drug design workflow using site identification by ligand competitive saturation","volume":"19","author":"Yu","year":"2023","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bcp.2026.118506_b0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.drudis.2018.01.035","article-title":"Progress with covalent small-molecule kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118506_b0040","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0045","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1021\/ci500175r","article-title":"Structure-based virtual screening approach for discovery of covalently bound ligands","volume":"54","author":"Toledo Warshaviak","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2026.118506_b0055","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/ph15111366","article-title":"Reactivity of covalent fragments and their role in fragment based drug discovery","volume":"15","author":"McAulay","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2026.118506_b0060","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1021\/acs.biochem.9b00293","article-title":"New electrophiles and strategies for mechanism-based and targeted covalent inhibitor design","volume":"58","author":"Ray","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118506_b0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acs.jmedchem.1c01719","article-title":"Discovery of cysteine-targeting covalent protein kinase inhibitors","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0070","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/acs.jmedchem.6b01815","article-title":"Determining cysteines available for covalent inhibition across the human kinome","volume":"60","author":"Zhao","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0075","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nature09472","article-title":"Quantitative reactivity profiling predicts functional cysteines in proteomes","volume":"468","author":"Weerapana","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118506_b0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.492","article-title":"Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine","volume":"7","author":"Hagel","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1073\/pnas.1313733111","article-title":"Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance","volume":"111","author":"Schwartz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118506_b0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118506_b0095","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118506_b0100","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/acs.chemrev.5c00001","article-title":"Advancing covalent ligand and drug discovery beyond cysteine","volume":"125","author":"Kim","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2026.118506_b0105","doi-asserted-by":"crossref","first-page":"15200","DOI":"10.1002\/anie.201707630","article-title":"Lysine-targeting covalent inhibitors","volume":"56","author":"Pettinger","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41557-021-00765-4","article-title":"A proteome-wide atlas of lysine-reactive chemistry","volume":"13","author":"Abbasov","year":"2021","journal-title":"Nat. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116386","article-title":"Recent progress in covalent warheads for in vivo targeting of endogenous proteins","volume":"47","author":"Shindo","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0120","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: an update","volume":"67","author":"Hillebrand","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103799","article-title":"The expanding repertoire of covalent warheads for drug discovery","volume":"28","author":"Mehta","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118506_b0130","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/ph16050663","article-title":"Recent advances in covalent drug discovery","volume":"16","author":"Schaefer","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2026.118506_b0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-biochem-061516-044805","article-title":"Lysine-Targeted Inhibitors and Chemoproteomic Probes","volume":"88","author":"Cuesta","year":"2019","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.bcp.2026.118506_b0140","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nchem.2826","article-title":"Global profiling of lysine reactivity and ligandability in the human proteome","volume":"9","author":"Hacker","year":"2017","journal-title":"Nat. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10858-014-9862-y","article-title":"pH-dependent random coil (1)H, (13)C, and (15)N chemical shifts of the ionizable amino acids: a guide for protein pKa measurements","volume":"60","author":"Platzer","year":"2014","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.bcp.2026.118506_b0150","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1073\/pnas.1010750108","article-title":"Large shifts in pKa values of lysine residues buried inside a protein","volume":"108","author":"Isom","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118506_b0155","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1021\/acs.chemrev.7b00305","article-title":"Electrostatic interactions in protein structure, folding, binding, and condensation","volume":"118","author":"Zhou","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2026.118506_b0160","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1038\/ncomms5202","article-title":"Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors","volume":"5","author":"Sanches","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118506_b0165","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/jacs.8b13248","article-title":"Assessing lysine and cysteine reactivities for designing targeted covalent kinase inhibitors","volume":"141","author":"Liu","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113786","article-title":"A sulfonyl fluoride derivative inhibits EGFR(L858R\/T790M\/C797S) by covalent modification of the catalytic lysine","volume":"225","author":"Ferlenghi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115671","article-title":"Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry","volume":"259","author":"Tang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0180","article-title":"Cell-active, reversible, and irreversible covalent inhibitors that selectively target the catalytic lysine of BCR-ABL kinase","volume":"61","author":"Chen","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0185","doi-asserted-by":"crossref","first-page":"17131","DOI":"10.1002\/anie.202105383","article-title":"Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL inhibitors*","volume":"60","author":"Quach","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0190","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/jacs.7b08979","article-title":"Selectively targeting the kinome-conserved lysine of PI3K\u03b4 as a general approach to covalent kinase inhibition","volume":"140","author":"Dalton","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0195","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2012.10","article-title":"Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity","volume":"14","author":"Smith","year":"2012","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bcp.2026.118506_b0200","first-page":"1","article-title":"Targeting protein\u2013protein interactions with reversible covalent modalities: non-cysteine chemistries","author":"Basu","year":"2026","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118506_b0205","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tips.2023.04.007","article-title":"Protein-protein interactions: developing small-molecule inhibitors\/stabilizers through covalent strategies","volume":"44","author":"Lucero","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.118506_b0210","doi-asserted-by":"crossref","first-page":"11383","DOI":"10.1021\/acs.jmedchem.9b01709","article-title":"Kinetic optimization of lysine-targeting covalent inhibitors of HSP72","volume":"62","author":"Pettinger","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0215","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/jacs.9b09684","article-title":"Ligand conformational bias drives enantioselective modification of a surface-exposed lysine on Hsp90","volume":"142","author":"Cuesta","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0220","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/anie.201611907","article-title":"An irreversible inhibitor of HSP72 that unexpectedly targets lysine-56","volume":"56","author":"Pettinger","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0225","article-title":"Lysine-targeting, covalent inhibitors of bromodomain BD1 of BET proteins in live cells and animals","volume":"64","author":"Li","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","article-title":"Covalent protein modification: the current landscape of residue-specific electrophiles","volume":"24","author":"Shannon","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0235","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tips.2023.08.014","article-title":"Covalent fragment approaches targeting non-cysteine residues","volume":"44","author":"Csorba","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.118506_b0240","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1038\/s41467-023-42632-5","article-title":"A simple method for developing lysine targeted covalent protein reagents","volume":"14","author":"Gabizon","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118506_b0245","doi-asserted-by":"crossref","first-page":"14568","DOI":"10.1021\/ja408322b","article-title":"An alkyne-aspirin chemical reporter for the detection of aspirin-dependent protein modification in living cells","volume":"135","author":"Bateman","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0250","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1038\/srep07896","article-title":"Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP)","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118506_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110203","article-title":"Isotope-labeled click-free probes to identify protein targets of lysine-targeting covalent reversible molecules","volume":"36","author":"Ma","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118506_b0260","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/MCB.16.4.1722","article-title":"Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction","volume":"16","author":"Wymann","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0265","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chembiol.2017.08.013","article-title":"Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products","volume":"24","author":"Grossman","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202316394","article-title":"Global reactivity profiling of the catalytic lysine in human kinome for covalent inhibitor development","volume":"63","author":"Tang","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0275","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1021\/acschembio.3c00803","article-title":"DNA-encoded library technology\u2014a catalyst for covalent ligand discovery","volume":"19","author":"Dickson","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0280","article-title":"Proteome-wide data guides the discovery of lysine-targeting covalent inhibitors using DNA-encoded chemical libraries","volume":"64","author":"Wu","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0285","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.70421","article-title":"Mapping functionally relevant tractable lysines of challenging protein targets by covalent fragment screening","volume":"27","author":"Csorba","year":"2026","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2026.118506_b0290","doi-asserted-by":"crossref","first-page":"46550","DOI":"10.1021\/jacs.5c17457","article-title":"Dioxazolones as masked isocyanate electrophiles for global profiling of lysine reactivity and ligandability","volume":"147","author":"Feng","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0295","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41467-025-56985-6","article-title":"Mass spectrometry methods and mathematical PK\/PD model for decision tree-guided covalent drug development","volume":"16","author":"Hossain","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118506_b0300","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118506_b0305","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent bruton's tyrosine kinase inhibitors PRN473 and PRN1008","volume":"65","author":"Owens","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0310","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0315","doi-asserted-by":"crossref","first-page":"17871","DOI":"10.1021\/jacs.5c01935","article-title":"Light-induced, lysine-targeting irreversible covalent inhibition of the human oxygen sensing hydroxylase factor inhibiting HIF","volume":"147","author":"Wu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0320","article-title":"Cell-active, irreversible covalent inhibitors targeting a surface-exposed non-catalytic lysine on aurora a kinase by using squarate chemistry","volume":"64","author":"Wang","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0325","doi-asserted-by":"crossref","first-page":"20076","DOI":"10.1021\/acs.jmedchem.4c01284","article-title":"Lysine-targeted covalent inhibitors of PI3K\u03b4 synthesis and screening by in situ interaction upgradation","volume":"67","author":"Yuan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0330","doi-asserted-by":"crossref","first-page":"17178","DOI":"10.1002\/anie.201811650","article-title":"Affinity enhancement of protein ligands by reversible covalent modification of neighboring lysine residues","volume":"57","author":"Dal Corso","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0335","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1039\/C6MD00017G","article-title":"Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-\u03b1-acetyl-l-lysine as an amine nucleophile","volume":"7","author":"Dahal","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.bcp.2026.118506_b0340","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.bcp.2026.118506_b0345","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acschembio.3c00805","article-title":"Reversible covalent inhibition\u2500desired covalent adduct formation by mass action","volume":"19","author":"Patel","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0350","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1039\/D5MD00050E","article-title":"Methods for kinetic evaluation of reversible covalent inhibitors from time-dependent IC(50) data","volume":"16","author":"Mader","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0355","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1021\/jacs.9b10377","article-title":"Discovery of lysine-targeted eif4e inhibitors through covalent docking","volume":"142","author":"Wan","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0360","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/jacs.6b08536","article-title":"Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes","volume":"139","author":"Zhao","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0365","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1021\/acs.jmedchem.9b01108","article-title":"Aryl-fluorosulfate-based lysine covalent pan-inhibitors of apoptosis protein (IAP) antagonists with cellular efficacy","volume":"62","author":"Baggio","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0370","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1021\/acs.jmedchem.3c00467","article-title":"Characterization of a potent and orally bioavailable lys-covalent inhibitor of apoptosis protein (IAP) Antagonist","volume":"66","author":"Udompholkul","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0375","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1021\/acsptsci.3c00156","article-title":"Targeted reversible covalent modification of a noncatalytic lysine of the krev interaction trapped 1 protein enables site-directed screening for protein-protein interaction inhibitors","volume":"6","author":"Francisco","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118506_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117183","article-title":"Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5","volume":"284","author":"Fei","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0385","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41586-024-08176-4","article-title":"Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation","volume":"637","author":"Craven","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118506_b0390","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nchembio.2174","article-title":"Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain","volume":"12","author":"Ak\u00e7ay","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0395","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1021\/jacs.2c11595","article-title":"2-Ethynylbenzaldehyde-based, lysine-targeting irreversible covalent inhibitors for protein kinases and nonkinases","volume":"145","author":"Chen","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0400","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1021\/jacs.4c18006","article-title":"O-cyanobenzaldehydes irreversibly modify both buried and exposed lysine residues in live cells","volume":"147","author":"Ling","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117948","article-title":"Discovery of novel covalent PI3K\u03b4 inhibitors bearing alaninamide moiety by lysine-targeted covalent strategy","volume":"297","author":"Yuan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0410","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1021\/acs.jmedchem.5c00408","article-title":"Lysine-targeted covalent strategy leading to the discovery of novel potent PROTAC-based PI3K\u03b4 degraders","volume":"68","author":"Yuan","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.108072","article-title":"Strategic design of lysine-targeted irreversible covalent NDM-1 inhibitors","volume":"34","author":"Ma","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118506_b0420","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chembiol.2015.07.018","article-title":"Identification and characterization of an irreversible inhibitor of CDK2","volume":"22","author":"Anscombe","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0425","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cbic.201600427","article-title":"Chemoselective preparation of clickable aryl sulfonyl fluoride monomers: a toolbox of highly functionalized intermediates for chemical biology probe synthesis","volume":"17","author":"Fadeyi","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2026.118506_b0430","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1039\/C8CS00960K","article-title":"The growing applications of SuFEx click chemistry","volume":"48","author":"Barrow","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bcp.2026.118506_b0435","doi-asserted-by":"crossref","first-page":"9430","DOI":"10.1002\/anie.201309399","article-title":"Sulfur(VI) fluoride exchange (SuFEx): another good reaction for click chemistry","volume":"53","author":"Dong","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0440","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202204565","article-title":"Aryl fluorosulfate based inhibitors that covalently target the sirt5 lysine deacylase","volume":"61","author":"Bolding","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0445","doi-asserted-by":"crossref","first-page":"21520","DOI":"10.1002\/anie.202008585","article-title":"Fragment-based stabilizers of protein-protein interactions through imine-based tethering","volume":"59","author":"Wolter","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118506_b0450","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1021\/acs.jmedchem.1c00401","article-title":"An exploration of chemical properties required for cooperative stabilization of the 14-3-3 interaction with NF-kappaB-utilizing a reversible covalent tethering approach","volume":"64","author":"Wolter","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0455","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300205","article-title":"Aldehyde-based inhibitors of the peptidoglycan o-acetylesterase Ape","volume":"24","author":"Voskoboinyk","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2026.118506_b0460","doi-asserted-by":"crossref","first-page":"10408","DOI":"10.1039\/D4SC02206H","article-title":"Key structural features to favour imines over hydrates in water: pyridoxal phosphate as a muse","volume":"15","author":"Esteve","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bcp.2026.118506_b0465","doi-asserted-by":"crossref","first-page":"15815","DOI":"10.1021\/ja906230n","article-title":"Substituent effects on the thermodynamic stability of imines formed from glycine and aromatic aldehydes: implications for the catalytic activity of pyridoxal-5'-phosphate","volume":"131","author":"Crugeiras","year":"2009","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0470","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/poc.941","article-title":"Structure\u2010stability correlations for imine formation in aqueous solution","volume":"18","author":"Godoy-Alc\u00e1ntar","year":"2005","journal-title":"J. Phys. Org. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0475","doi-asserted-by":"crossref","first-page":"24233","DOI":"10.1021\/jacs.4c04314","article-title":"Aminomethyl salicylaldehydes lock onto a surface lysine by forming an extended intramolecular hydrogen bond network","volume":"146","author":"Weaver","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0480","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41589-022-01019-1","article-title":"Reversible lysine-targeted probes reveal residence time-based kinase selectivity","volume":"18","author":"Yang","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118506_b0485","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300743","article-title":"A tight contact: the expanding application of salicylaldehydes in lysine-targeting covalent drugs","volume":"25","author":"Mason","year":"2024","journal-title":"Chembiochem"},{"key":"10.1016\/j.bcp.2026.118506_b0490","doi-asserted-by":"crossref","unstructured":"C. Gampe, V.A. Verma, Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients, J Med Chem, 63 (2020) 14357-14381.","DOI":"10.1021\/acs.jmedchem.0c01177"},{"key":"10.1016\/j.bcp.2026.118506_b0495","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2305833","article-title":"Boronic acid inhibitors of penicillin-binding protein 1b: serine and lysine labelling agents","volume":"39","author":"Kollar","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118506_b0500","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1021\/ja303436y","article-title":"Iminoboronates: a new strategy for reversible protein modification","volume":"134","author":"Cal","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118506_b0505","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1038\/ncomms7561","article-title":"Targeting bacteria via iminoboronate chemistry of amine-presenting lipids","volume":"6","author":"Bandyopadhyay","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118506_b0510","doi-asserted-by":"crossref","first-page":"10689","DOI":"10.1039\/D1CC03976H","article-title":"Site-selective lysine conjugation methods and applications towards antibody-drug conjugates","volume":"57","author":"Haque","year":"2021","journal-title":"Chem. Commun. (Camb)"},{"key":"10.1016\/j.bcp.2026.118506_b0515","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17460441.2021.1832079","article-title":"Approaches to mitigate the risk of serious adverse reactions in covalent drug design","volume":"16","author":"Baillie","year":"2021","journal-title":"Expert Opin. Drug Discov."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:47:06Z","timestamp":1791060426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":103,"alternative-id":["S0006295226008488"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118506","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lysine-targeted covalent inhibitors: mechanistic advances, pharmacological perspectives and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118506"}}